Literature DB >> 10376981

Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients.

J M Silva1, G Dominguez, M J Villanueva, R Gonzalez, J M Garcia, C Corbacho, M Provencio, P España, F Bonilla.   

Abstract

Hypermethylation of exon 1 of p16INK4a was examined in tumour and plasma DNA of a series of breast cancer patients. De novo methylation was observed in the tumours of eight patients (23%), and in plasma DNA in five (14%) of these eight patients. Our data show that de novo methylation of exon 1 of p16INK4a can be demonstrated in plasma DNA of breast cancer patients, a fact that provides additional evidence of the tumour-related origin of free plasma DNA in cancer patients.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10376981      PMCID： PMC2362379          DOI： 10.1038/sj.bjc.6690495

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  29 in total

1.  Mutations and altered expression of p16INK4 in human cancer.

Authors:  A Okamoto; D J Demetrick; E A Spillare; K Hagiwara; S P Hussain; W P Bennett; K Forrester; B Gerwin; M Serrano; D H Beach
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

2.  Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers.

Authors:  T Nobori; K Miura; D J Wu; A Lois; K Takabayashi; D A Carson
Journal:  Nature       Date:  1994-04-21       Impact factor: 49.962

3.  A cell cycle regulator potentially involved in genesis of many tumor types.

Authors:  A Kamb; N A Gruis; J Weaver-Feldhaus; Q Liu; K Harshman; S V Tavtigian; E Stockert; R S Day; B E Johnson; M H Skolnick
Journal:  Science       Date:  1994-04-15       Impact factor: 47.728

4.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.

Authors:  M Serrano; G J Hannon; D Beach
Journal:  Nature       Date:  1993-12-16       Impact factor: 49.962

5.  Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.

Authors:  J G Herman; F Latif; Y Weng; M I Lerman; B Zbar; S Liu; D Samid; D S Duan; J R Gnarra; W M Linehan
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

6.  Microsatellite analysis of plasma DNA from patients with clear cell renal carcinoma.

Authors:  C Goessl; R Heicappell; R Münker; P Anker; M Stroun; H Krause; M Müller; K Miller
Journal:  Cancer Res       Date:  1998-10-15       Impact factor: 12.701

7.  Neoplastic characteristics of the DNA found in the plasma of cancer patients.

Authors:  M Stroun; P Anker; P Maurice; J Lyautey; C Lederrey; M Beljanski
Journal:  Oncology       Date:  1989       Impact factor: 2.935

Review 8.  DNA methylation and cancer.

Authors:  P W Laird; R Jaenisch
Journal:  Hum Mol Genet       Date:  1994       Impact factor: 6.150

9.  Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia.

Authors:  V Vasioukhin; P Anker; P Maurice; J Lyautey; C Lederrey; M Stroun
Journal:  Br J Haematol       Date:  1994-04       Impact factor: 6.998

10.  Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon.

Authors:  J P Issa; Y L Ottaviano; P Celano; S R Hamilton; N E Davidson; S B Baylin
Journal:  Nat Genet       Date:  1994-08       Impact factor: 38.330
View more
  30 in total

1.  Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients.

Authors:  Yoon Hee Cho; Jing Shen; Marilie D Gammon; Yu-Jing Zhang; Qiao Wang; Karina Gonzalez; Xinran Xu; Patrick T Bradshaw; Susan L Teitelbaum; Gail Garbowski; Hanina Hibshoosh; Alfred I Neugut; Jia Chen; Regina M Santella
Journal:  Breast Cancer Res Treat       Date:  2011-08-12       Impact factor: 4.872

2.  Polycyclic aromatic hydrocarbon (PAH)-DNA adducts and breast cancer: modification by gene promoter methylation in a population-based study.

Authors:  Alexandra J White; Jia Chen; Lauren E McCullough; Xinran Xu; Yoon Hee Cho; Susan L Teitelbaum; Alfred I Neugut; Mary Beth Terry; Hanina Hibshoosh; Regina M Santella; Marilie D Gammon
Journal:  Cancer Causes Control       Date:  2015-09-25       Impact factor: 2.506

3.  Whole genome amplification of plasma-circulating DNA enables expanded screening for allelic imbalance in plasma.

Authors:  Jin Li; Lyndsay Harris; Harvey Mamon; Matthew H Kulke; Wei-Hua Liu; Penny Zhu; G Mike Makrigiorgos
Journal:  J Mol Diagn       Date:  2006-02       Impact factor: 5.568

4.  Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients.

Authors:  Thomas E Liggett; Anatoliy A Melnikov; Jeffrey R Marks; Victor V Levenson
Journal:  Int J Cancer       Date:  2010-04-05       Impact factor: 7.396

Review 5.  Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology.

Authors:  Bert Gold; Milena Cankovic; Larissa V Furtado; Frederick Meier; Christopher D Gocke
Journal:  J Mol Diagn       Date:  2015-05       Impact factor: 5.568

Review 6.  Analysis of circulating tumor DNA in breast cancer as a diagnostic and prognostic biomarker.

Authors:  Mersedeh Rohanizadegan
Journal:  Cancer Genet       Date:  2018-02-24

Review 7.  Use of NCCN Guidelines, Other Guidelines, and Biomarkers for Colorectal Cancer Screening.

Authors:  Christina D Williams; William M Grady; Leah L Zullig
Journal:  J Natl Compr Canc Netw       Date:  2016-11       Impact factor: 11.908

8.  The influence of one-carbon metabolism on gene promoter methylation in a population-based breast cancer study.

Authors:  Xinran Xu; Marilie D Gammon; Elizabeth Jefferson; Yujing Zhang; Yoon Hee Cho; James G Wetmur; Susan L Teitelbaum; Patrick T Bradshaw; Mary Beth Terry; Gail Garbowski; Hanina Hibshoosh; Alfred I Neugut; Regina M Santella; Jia Chen
Journal:  Epigenetics       Date:  2011-11-01       Impact factor: 4.528

9.  DNA methylation in circulating tumour DNA as a biomarker for cancer.

Authors:  Ruth E Board; Lucy Knight; Alastair Greystoke; Fiona H Blackhall; Andrew Hughes; Caroline Dive; Malcolm Ranson
Journal:  Biomark Insights       Date:  2008-01-25

Review 10.  Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers.

Authors:  Yoshinaga Okugawa; William M Grady; Ajay Goel
Journal:  Gastroenterology       Date:  2015-07-26       Impact factor: 22.682
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.